Rare and Orphan Diseases
Total Trials
1
As Lead Sponsor
0
As Collaborator
Total Enrollment
120
NCT06174220
Targeted Therapy With Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic Cardiomyopathy
Phase: Phase 2
Role: Collaborator
Start: Mar 21, 2025
Completion: Jul 1, 2027
Loading map...